Summary
Samples for drug development, a bulk plant ingredient used in a cosmetic product, herbal teas, or microorganisms that contribute to biotechnological processes …. do all of these fall under ABS law? A lot of confusion surrounds the activities and products covered by ABS. The Convention on Biological Diversity (CBD) addresses “genetic resources” and “biological resources”, but what does that mean in practice to local groups, researchers, indigenous peoples, companies, and even governments? Stakeholders tend to view ABS in many different ways, and partly this is because what ABS applies to – that is, its scope – has become exceedingly broad. A quick look at some existing national and international frameworks shows ABS covering biological materials, genetic resources, derived products, indigenous peoples´ traditional knowledge, biotrade, and more recently “digital sequence information”.
ABS policy has provided a home for numerous orphaned ethical issues associated with biodiversity, traditional knowledge, genetic resources, and advanced science and technology. It has been all things to all people and convened invaluable dialogues over the last few decades. But its implementation has always lagged behind its promise, and one of the challenges can be found in the ambiguity around what it actually regulates. This is a pressing matter today as policy makers and others grapple with the implications of DSI for ABS. This webinar will review the origins of scope within the CBD, how it evolved over the following few decades, and where we find ourselves today. Contributors will share views on the appropriate scope for national laws, some of the lessons learned, and possible approaches to addressing challenges today.